Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2026)

Amphastar Pharmaceuticals has reported Long-Term Investments for 7 years, with the latest figure at $16.3 million in Q2 2026.

• On a quarterly basis, Long-Term Investments rose 34.71% year-over-year to $16.3 million in Q2 2026; TTM through Jun 2026 was $16.3 million, a 34.71% increase from a year earlier, with the FY2025 full-year figure at $14.5 million, up 31.87% from the prior year.
• Long-Term Investments was $16.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $14.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $16.3 million in Q2 2026, with the low at $3.4 million in Q2 2022.
• Average Long-Term Investments over 5 years is $9.6 million, with a median of $10.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments jumped 226.33% in 2023, then sank 30.09% in 2025.
• Over 5 years, Long-Term Investments stood at $4.5 million in 2022, then surged by 226.33% to $14.7 million in 2023, then decreased by 25.12% to $11.0 million in 2024, then soared by 31.87% to $14.5 million in 2025, then advanced by 12.41% to $16.3 million in 2026.
• The last three Long-Term Investments figures came in at $16.3 million (Q2 2026), $14.4 million (Q1 2026), and $14.5 million (Q4 2025), per Business Quant data.